<code id='572D622D73'></code><style id='572D622D73'></style>
    • <acronym id='572D622D73'></acronym>
      <center id='572D622D73'><center id='572D622D73'><tfoot id='572D622D73'></tfoot></center><abbr id='572D622D73'><dir id='572D622D73'><tfoot id='572D622D73'></tfoot><noframes id='572D622D73'>

    • <optgroup id='572D622D73'><strike id='572D622D73'><sup id='572D622D73'></sup></strike><code id='572D622D73'></code></optgroup>
        1. <b id='572D622D73'><label id='572D622D73'><select id='572D622D73'><dt id='572D622D73'><span id='572D622D73'></span></dt></select></label></b><u id='572D622D73'></u>
          <i id='572D622D73'><strike id='572D622D73'><tt id='572D622D73'><pre id='572D622D73'></pre></tt></strike></i>

          Home / Wikipedia / leisure time

          leisure time


          leisure time

          author:knowledge    Page View:9
          translucent 3D DNA helix with blue and purple background
          Adobe

          Verve Therapeutics said Monday that it had received clearance from the Food and Drug Administration to conduct a clinical trial in the U.S. of its experimental, gene-editing treatment for a common form of heart disease.

          The FDA’s action removes a clinical hold on Verve’s CRISPR-based therapy, called VERVE-101, that was placed on it last November. Verve now intends to recruit participants from U.S. sites into a Phase 1 study that’s been underway since last year in New Zealand and the United Kingdom.

          advertisement

          “We’re thrilled to get this clearance for VERVE-101,” said Verve CEO Sek Kathiresan. “Our study is called HEART-1 and our plan now is to activate U.S. sites.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In